Our Focus

NeuroPn Therapeutics is developing novel therapies for the treatment of neurodegenerative diseases with focus on painful peripheral neuropathy and Parkinson’s disease.

Painful Peripheral Neurotheraphy

Painful peripheral neuropathy [PPN] is caused by an injury or inflammation of the nervous system. PPN is associated with diseases such as diabetes or use of drugs such as chemotherapeutic agents or antiviral drugs. Peripheral neuropathies may involve injured sensory, motor, or autonomic nervous system nerves. In the central nervous system, injury, stroke, or disease in the brain or spinal cord can also generate a state of chronic neuropathic pain. Pain associated with acute neuronal damage can also transition to chronic pain.

Peripheral neuropathic pain affects over 16 million Americans and is causally linked to a number of diseases including diabetes, cancer, shingles, infections such as HIV, chronic back pain, stroke, and multiple sclerosis . The most commonly prescribed drug classes for neuropathic pain such as antidepressants, serotonin-norepinephrine reuptake inhibitors, anticonvulsants and opioids, have limited efficacy and dose-limiting adverse effects. No single agent provides optimal balance of safety, tolerability, and efficacy. As a result, treatment of peripheral neuropathy continues to be characterized by a high rate of polypharmacy and switching from one agent to another.

All currently approved treatments for PPN modulate neuronal targets and provide only symptomatic relief.

There are no FDA-approved therapies for prevention or reversal of peripheral neuropathy.

There is urgent need for non-opioid, safe and effective therapies for neuropathic and chronic pain.

Parkinson's Disease

NeuroPn's enzyme inhibition approach shows marked improvement in locomotor activity and significant inhibition of neuronal degeneration; differentiating from current satandard of care (L-DOPA).

Parkinsons’s disease (PD) is a chronic and progressive degenerative movement disorder that affects over 1.5 million Americans. Currently marketed dopamine replacement therapy can alleviate motor symptoms in PD, but there are no therapies that target the underlying neurodegenerative processes. Despite intense research, molecular mechanisms causing neuronal loss are not fully understood which has hampered the development of new drugs and disease modifying therapies.

Neuroinflammation and mitochondrial dysfunction with associated oxidative/endoplasmic reticulum (ER) stress all work synergistically to accelerate Parkinson’s disease (PD) progression.

There is urgent need for novel therapies that can protect neurons and halt or reverse disease progression.